ID: h-a1edc6af93
Hypothesis
Cortical Layer 5 Pyramidal Neuron GluN2B-Mediated Hyperactivity Drives Tau Secretion Into Glymphatic Flow
Hyperactive GluN2B in L5 corticothalamic neurons increases extracellular glutamate, activating astrocytes and oligodendrocytes to release tau via exosome pathways.
🧬 GRIN2B (L5 pyramidal neurons); downstream: ADAM10/ADAM17🩺 neuroscience🎯 Composite 68%💱 $0.58▼13.4%proposed
EvidencePending (0%)📖 0 cit🗣 1 debates✓ 3 support✗ 2 oppose
✓ All Quality Gates Passed
🧪 Overview
Hyperactive GluN2B in L5 corticothalamic neurons increases extracellular glutamate, activating astrocytes and oligodendrocytes to release tau via exosome pathways. Enhanced neuronal activity simultaneously increases interstitial flow, redirecting tau-seed-bearing exosomes into perivascular channels for clearance—or facilitating prion-like spreading. Links activity-dependent tau release to glymphatic routing.
🧬 Mechanism
🔗 Mechanism from KG for GRIN2B (L5 pyramidal neurons); downstream: ADAM10/ADAM17
Auto-built from this analysis's top knowledge-graph edges.
graph TD
GluN2B["GluN2B"] -->|regulates| thalamic_burst_firing["thalamic burst firing"]
slow_wave_oscillations["slow-wave oscillations"] -->|enhances| glymphatic_clearance["glymphatic_clearance"]
tau_pathology["tau_pathology"] -.->|inhibits| glymphatic_clearance_effi["glymphatic clearance efficiency"]
Trem2["Trem2"] -->|regulates| tau_phagocytosis["tau phagocytosis"]
TREM2_deficiency["TREM2 deficiency"] -->|associated with| Tau_Clearance["Tau Clearance"]
Cx3Cl1["Cx3Cl1"] -->|associated with| Cx3Cr1["Cx3Cr1"]
Cx3Cr1_1["Cx3Cr1"] -->|regulates| tau_phagocytosis_2["tau phagocytosis"]
Memantine["Memantine"] -->|enhances| CSF_tracer_clearance["CSF tracer clearance"]
GluN2B_3["GluN2B"] -->|associated with| cortical_slow_wave_oscill["cortical slow-wave oscillations"]
oxidative_stress["oxidative_stress"] -->|causes| AQP4_oxidation["AQP4 oxidation"]
GLUTAMATE_EXCITOTOXICITY["GLUTAMATE EXCITOTOXICITY"] -->|enhances| Tau_Secretion["Tau Secretion"]
sess_SRB_2026_04_28_h_var["sess_SRB-2026-04-28-h-var-e2b5a7e7db_task_9aae8fc5"] -->|causal extracted| processed["processed"]
style GluN2B fill:#4fc3f7,stroke:#333,color:#000
style thalamic_burst_firing fill:#4fc3f7,stroke:#333,color:#000
style slow_wave_oscillations fill:#4fc3f7,stroke:#333,color:#000
style glymphatic_clearance fill:#81c784,stroke:#333,color:#000
style tau_pathology fill:#ef5350,stroke:#333,color:#000
style glymphatic_clearance_effi fill:#4fc3f7,stroke:#333,color:#000
style Trem2 fill:#4fc3f7,stroke:#333,color:#000
style tau_phagocytosis fill:#4fc3f7,stroke:#333,color:#000
style TREM2_deficiency fill:#4fc3f7,stroke:#333,color:#000
style Tau_Clearance fill:#4fc3f7,stroke:#333,color:#000
style Cx3Cl1 fill:#4fc3f7,stroke:#333,color:#000
style Cx3Cr1 fill:#4fc3f7,stroke:#333,color:#000
style Cx3Cr1_1 fill:#4fc3f7,stroke:#333,color:#000
style tau_phagocytosis_2 fill:#4fc3f7,stroke:#333,color:#000
style Memantine fill:#ce93d8,stroke:#333,color:#000
style CSF_tracer_clearance fill:#ce93d8,stroke:#333,color:#000
style GluN2B_3 fill:#4fc3f7,stroke:#333,color:#000
style cortical_slow_wave_oscill fill:#4fc3f7,stroke:#333,color:#000
style oxidative_stress fill:#4fc3f7,stroke:#333,color:#000
style AQP4_oxidation fill:#4fc3f7,stroke:#333,color:#000
style GLUTAMATE_EXCITOTOXICITY fill:#4fc3f7,stroke:#333,color:#000
style Tau_Secretion fill:#4fc3f7,stroke:#333,color:#000
style sess_SRB_2026_04_28_h_var fill:#4fc3f7,stroke:#333,color:#000
style processed fill:#4fc3f7,stroke:#333,color:#000⚖️ Evidence
⚖️ Evidence Matrix3 supports2 contradicts
Contradicts
Activity-dependent tau release studies mostly in vitro; trans-synaptic spreading uses different mechanisms
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — GRIN2B
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for GRIN2B (L5 pyramidal neurons); downstream: ADAM10.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↘
Falling
7d Momentum
▼ 1.0%
Volatility
Low
0.0022
Events (7d)
3
Price History
▼13.4%💾 Resource Usage
No resource usage or linked notebooks recorded for this hypothesis yet.
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF we genetically ablate ADAM10/ADAM17 in astrocytes using Aldh1l1-Cre;Adam10/17 flox mice crossed with rTg4510 tauopathy mice, THEN astrocyte-derived exosome tau content will decrease by ≥50% and gly | ≥50% decrease in astrocyte exosome tau content, ≥30% improvement in glymphatic clearance rate, with no compensatory changes in neuronal firing properties | — no observation — | pending | 0.58 |
| IF we selectively inhibit GluN2B-containing NMDA receptors in L5 corticothalamic pyramidal neurons using ifenprodil (10 mg/kg, i.p., 2 weeks) in 6-month-old 5xFAD mice, THEN extracellular tau concentr | ≥40% reduction in extracellular tau concentration and ≥40% reduction in tau seeding activity in perivascular fluid within 2 weeks of continuous GluN2B inhibitio | — no observation — | pending | 0.65 |
🔮 Falsifiable Predictions (2)
pendingconf 65%
IF we selectively inhibit GluN2B-containing NMDA receptors in L5 corticothalamic pyramidal neurons using ifenprodil (10 mg/kg, i.p., 2 weeks) in 6-month-old 5xFAD mice, THEN extracellular tau concentration in interstitial fluid (measured via microdialysis) will decrease by ≥40% and perivascular tau
Predicted outcome: ≥40% reduction in extracellular tau concentration and ≥40% reduction in tau seeding activity in perivascular fluid within 2 weeks of continuous GluN2B
Falsification: No significant change (<20%) in interstitial or perivascular tau levels, or paradoxically increased tau after GluN2B inhibition, indicating GluN2B is not the primary driver
pendingconf 58%
IF we genetically ablate ADAM10/ADAM17 in astrocytes using Aldh1l1-Cre;Adam10/17 flox mice crossed with rTg4510 tauopathy mice, THEN astrocyte-derived exosome tau content will decrease by ≥50% and glymphatic clearance efficiency (MRI Gd-DTPA perivascular flux) will increase by ≥30%, while neuronal a
Predicted outcome: ≥50% decrease in astrocyte exosome tau content, ≥30% improvement in glymphatic clearance rate, with no compensatory changes in neuronal firing propert
Falsification: No change in astrocyte exosome tau despite ADAM10/17 deletion, indicating these proteases are not required for activity-dependent tau release; or impaired rather than enhanced glymphatic clearance
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesizer
| source | v1_phase_c_backfill |
| origin_type | debate_synthesizer |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.